Meral Kanbak

Prof. Dr. Meral Kanbak

Department of Anesthesiology and Reanimation, Yozgat Bozok University, Yozgat, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
AGAygun Guler
Aygun Guler
TSTulin Satilmis
Tulin Satilmis
SASeda B. Akinci
Seda B. Akinci
BCBilge Celebioglu
Bilge Celebioglu
MKMeral Kanbak
Meral Kanbak
Myoclonic movements and pain on injection are common problems during induction of anesthesia with etomidate. We investigated the influence of pretreatment with magnesium and two doses of ketamine on the incidence of etomidate-induced myoclonus and pain. A prospective double-blind study was performed on 100 ASA physical status I-III patients who were randomized into 4 groups according to the pretreatment drug: ketamine 0.2 mg/kg, ketamine 0.5 mg/kg, magnesium sulfate (Mg) 2.48 mmol, or normal saline. Ninety seconds after the pretreatment, anesthesia was induced with etomidate 0.2 mg/kg. Vecuronium 0.1 mg/kg was used as the muscle relaxant. An anesthesiologist, blinded to group allocation, recorded the myoclonic movements, pain, and sedation on a scale between 0-3. Nineteen of the 25 patients receiving Mg (76%) did not have myoclonic movements after the administration of etomidate, whereas 18 patients (72%) in the ketamine 0.5 mg/kg, 16 patients (64%) in the ketamine 0.2 mg/kg, and 18 patients (72%) in the control group experienced myoclonic movements (P < 0.05). We conclude that Mg 2.48 mmol administered 90 s before the induction of anesthesia with etomidate is effective in reducing the severity of etomidate-induced myoclonic muscle movements and that ketamine does not reduce the incidence of myoclonic movements.

1 October 2012 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
PDF file
NÖNihal Gökbulut Özarslan
Nihal Gökbulut Özarslan
BABanu Ayhan
Banu Ayhan
MKMeral Kanbak
Meral Kanbak
BÇBilge Çelebioğlu
Bilge Çelebioğlu
MDMetin Demircin
Metin Demircin
ÜAÜlkü Aypar
Ülkü Aypar

1 May 1997 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
SKS. Kahraman
S. Kahraman
HAH. Altunkaya
H. Altunkaya
BÇB. Çelebíoǧlu
B. Çelebíoǧlu
MKMeral Kanbak
Meral Kanbak
ÎPÎi. Paslaolu
Îi. Paslaolu
KEK. Erdem
K. Erdem

1 May 2003 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Closed access
PDF file
DDDidem Dal
Didem Dal
MKMeral Kanbak
Meral Kanbak
MCMeltem Caglar
Meltem Caglar
UAUlku Aypar
Ulku Aypar

1 June 1999 in Canadian Journal of Anesthesia/Journal canadien d'anesthésie
Verified
Journal Article
Open access
PDF file
MKMeral Kanbak
Meral Kanbak
To report three patients who developed heparin resistance during cardiac surgery which was successfully managed with 1000 U Antithrombin III (AT III). We observed heparin resistance prior to cardiopulmonary bypass (CPB) in one patient and during the CPB in two patients. In the first patient who was scheduled for mitral valve replacement, although heparin was administered sequentially up to 500 U · kg−1 prior the CPB, the ACT value was 354 sec. After 1,000 U ATIII were administered the ACT was 395 sec and CPB was initiated. The ACT remained between 496 and 599 sec throughout CPB and a total of 260 mg protamine sulfate was given. In the other two patients following 300 U · kg−1 heparin, the ACT was up to 400 sec and CPB was initiated. During CPB, ACT were decreased 360 sec and 295 sec in patients II and III respectively. Although heparin was added 1,500 U, ACT increased to ≥ 400 sec could not be achieved. In the second patient AT III activity was found 10%. After the administration of 1,000 U ATIII, ATIII activity was found to be 67% 40 min later and ACT were increased up to 400 sec. There was no thrombosis within the extracorporeal circuit, additional heparin was not required, less protamine was administered (≤, 3 mg · kg−1) and no excessive postoperative bleeding was observed in all patients. We recommend that AT III supplementation should be considered to manage heparin resistance prior or during CPB in patients undergoing open heart surgery. Présenter le cas de trois patients qui ont développé une résistance à l’héparine, pendant une intervention cardiaque, traitée avec succès avec 1 000 U d’antithrombine III (AT III). Chez l’un des patients, la résistance à l’héparine s’est manifestée avant la circulation extracorporelle (CEC), mais pendant la CEC chez les deux autres patients. Dans le cas du premier patient pour qui le remplacement de la valvule mitrale avait été planifié, le temps de coagulation activée (TCA) a été de 354 s malgré l’administration séquentielle d’héparine, jusqu’à 500 U · kg−1 avant la CEC. Après l’administration de 1 000 U d’AT III, le TCA était de 395 s et la CEC a été amorcée. Le TCA est demeuré entre 496 et 599 s tout au long de la CEC et 260 mg de sulfate de protamine ont été administrés en tout. Chez les deux autres patients, la CEC a été instaurée à la suite de l’administration de 300 U · kg−1 d’héparine alors que le TCA allait jusqu’à 400 s. Pendant la CEC, le TCA est baissé à 360 s et 295 s chez les patients II et III, respectivement. En dépit de 1 500 U d’héparine supplémentaires, le TCA n’a pu être augmenté à 400 s. Chez le deuxième patient, l’activité de l’AT III était de 10 %. L’administration de 1 000 U d’AT III a amené l’activité de l’AT III à 67 %, 40 min plus tard, et les TCA se sont élevés jusqu’à 400 s. Chez tous les patients, il n’y a pas eu de thrombose à l’intérieur du circuit extracorporel, l’héparine supplémentaire n’a pas été nécessaire, l’administration de protamine a été faible (3 mg · kg−1) et il n’y a pas eu de saignements postopératoires excessifs. Nous recommandons l’administration d’AT III supplémentaire pour traiter la résistance à l’héparine avant, ou pendant la CEC, lors d’interventions à coeur ouvert.

12 October 2005 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
SASeda B. Akinci
Seda B. Akinci
NUNadir Ulu
Nadir Ulu
OYOmer Z. Yondem
Omer Z. Yondem
PFPinar Firat
Pinar Firat
MGM. Oguz Guc
M. Oguz Guc
UAUlku Aypar
Ulku Aypar